MOH Statement on Cancer Drug Vitrakvi

MOH Statement on Cancer Drug Vitrakvi

MOH Statement on Cancer Drug Vitrakvi


In reference to what is being recently circulated in the local and international media, the audio-visual and print media, about the approval of the Food and Drug Administration (FDA) for the Larotrectinab drug, known as Vitrakvi.  

In order to avoid any ambiguity in this regard, the Ministry of Health (MOH) would like to clarify that the mentioned drug has been tested on a limited number of patients by the FDA (55 patients only, including 12 patient under the age of 18 years).

The preliminary results showed that 73% of these patients have responded to the therapy within the first nine-month of taking the drug. However, the percentage started to decline gradually, until it reached 39% only during the first year.

It is important to highlight that this drug works in an iterative manner through preventing the growth of tumors caused by a rare genetic disorder (genetic mutation causing some kinds of cancers). Therefore, the drug targets certain types of cancers associated with this genetic defect but not all the cancers types.

The drug has a number of side-effects that have been observed on the patients who have been treated by this medicine including the fatigue, sickness, vomiting, high liver enzymes, dizziness, diarrhea and constipation.